Why is Bristol Myers seeking to expand Camzyos use to adolescents?

The company aims to address an unmet medical need in adolescents with obstructive HCM, as no approved alternatives currently exist for this age group.

When might the FDA decide on expanding Camzyos use?

No specific timeline has been announced, but regulatory reviews typically take several months.

What is the potential impact of approval on BMY stock?

Approval could boost Camzyos revenues and support Bristol Myers' stock, but the impact depends on market size and approval terms.

Bristol Myers Seeks FDA Nod for Camzyos in Adolescents

Bristol-Myers Squibb (BMY) is under FDA review for expanding Camzyos to adolescents with obstructive hypertrophic cardiomyopathy. Approval could boost the company's cardiovascular pipeline.

June 16, 2026

2 min read

Source: Zacks

Bristol-Myers Squibb (BMY) is seeking regulatory approval from the U.S. Food and Drug Administration (FDA) to expand the use of its drug Camzyos to adolescents with obstructive hypertrophic cardiomyopathy (HCM).

Details of the Action

Bristol Myers has submitted a supplemental application to the FDA to include adolescent patients with obstructive HCM in the indication for Camzyos (mavacamten). The drug was previously approved for adults with the condition in 2022.

Company's Position

The company believes that expanding the indication to adolescents will strengthen its cardiovascular portfolio and address an unmet medical need in this age group.

Precedents and Context

Camzyos was approved for adults in 2022 and is considered a leading therapy for obstructive HCM. This potential expansion is part of Bristol Myers' broader strategy to bolster its cardiovascular pipeline.

Potential Financial Impact

If approved, the expansion could significantly increase Camzyos revenues, as there are currently no approved alternatives for adolescents. The company has not provided specific financial guidance.

Frequently Asked Questions

Camzyos (mavacamten) is a drug used to treat obstructive hypertrophic cardiomyopathy in adults, working by inhibiting myosin to reduce heart muscle contraction.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.